FindTrial
Sign In

Evaluate the efficacy of different preoperative neoadjuvant therapy regimens for resectable esophageal cance

Evaluate the efficacy of different preoperative neoadjuvant therapy regimens for resectable esophageal cancer: a multicenter, retrospective, real-world clinical study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600119590
Enrollment
Unknown
Registered
2026-02-28
Start date
2025-01-01
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Resectable locally advanced Esophageal Cancer

Interventions

Group A: Preoperative chemoradiotherapy (CRT) group :None
Group B: Preoperative chemotherapy (CT) group :None
Group C: Preoperative chemoimmunotherapy (CIT) group :None
Group D: Preoperative chemoradiotherapy plus immunotherapy (CRT+IO) group:None

Sponsors

Henan Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Age >=18 years; 2. Histologically or cytologically confirmed esophageal cancer; 3. Received preoperative neoadjuvant therapy; 4. Underwent surgical resection for esophageal cancer.

Exclusion criteria

Exclusion criteria: 1. Presence of malignancies other than esophageal cancer; 2. History of other malignant tumors within the past 5 years (except for effectively controlled conditions such as basal cell carcinoma of the skin, cervical carcinoma in situ, and ductal carcinoma in situ of the breast).

Design outcomes

Primary

MeasureTime frame
Overall Survival;—

Secondary

MeasureTime frame
Progress free survival;Pathological Complete Response;—

Countries

China

Contacts

Public ContactXiaoli Zheng

Henan Cancer Hospital

ziye0705@163.com+86 371 65587765

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026